Accueil   Diary - News   All news Poxel


Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, currently focused on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. Poxel's innovative pipeline of first-in-class products with disease-modifying mechanisms of action offers the potential for safer and more effective therapies for type 2 diabetes. Its lead compound, Imeglimin, has completed Phase 2 clinical development for type 2 diabetes in the EU and US, achieving proof-of-concept in two Phase 2a clinical trials and met primary and secondary endpoints in a Phase 2b dose-ranging trial.



Poxel announces positive top line results for Imeglimin Phase 2b study in Japan for the treatment of yype 2 diabetes


• Imeglimin Phase 2b trial in 299 Japanese patients achieved statistical significance for the primary and key secondary endpoints 


• Imeglimin Phase 3 program in Japan is anticipated to initiate in the fourth quarter of 2017

• The Japanese diabetes market is fast-growing and anticipated to reach approximately $6B by 2020


Press releases :


Poxel Announces Positive Top Line Results for Imeglimin Phase 2b Study


Poxel Presents Imeglimin Japanese Phase 1 Results

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree